logo
Plus   Neg
Share
Email

Novartis Gets Approval From European Commission For Jakavi - Quick Facts

Incyte Corporation (INCY) announced its strategic collaborator, Novartis, received approval from the European Commission for Jakavi, or INC424, ruxolitinib, an oral JAK 1 and JAK 2 inhibitor discovered by Incyte, for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, or chronic idiopathic myelofibrosis, post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis.

Myelofibrosis is a life-threatening blood cancer associated with progressive, debilitating symptoms that can severely impact quality of life and shorten survival. Novartis said the European Commission's decision was based on positive findings from the COMFORT, or COntrolled MyeloFibrosis Study with ORal JAK Inhibitor Therapy, clinical trial program.

Incyte entered into a worldwide collaboration and license agreement with Novartis in 2009. Novartis received exclusive rights to the development and potential commercialization of ruxolitinib in all hematology-oncology indications outside of the United States. Incyte retained exclusive rights for the development and commercialization of ruxolitinib in the United States, and received approval from the U.S. Food and Drug Administration in November 2011 for ruxolitinib, marketed in the United States under the brand name Jakafi.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Following the mixed performance seen last week, stocks are likely to move to the downside in early trading on Monday. The major index futures are currently pointing to a notably lower open for the markets, with the Dow futures down by 212 points. *European, Asian shares fall on Monday amid escalating U.S.-China trade tensions *Oil extends losses ahead of OPEC meeting later this week *U.S. Federal Reserve Chair Jerome Powell said "the economy is doing very well" *Goldman Sachs model now points to higher U.S. Q2 GDP growth of 4% *Google... Russia's biggest two banks, Sberbank and Alfa Bank, are planning to test several private banking products based on cryptocurrencies in a regulatory sandbox environment hosted by the Russian central bank, the Kommersant newspaper reported.
Follow RTT